Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?Sarah Marmol, Jason Margolesky, Matthew Feldman et al.|CNS Drugs|2021Cited by 23
Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the ClinicMatthew Feldman, Jason Margolesky, Sarah Marmol|Therapeutics and Clinical Risk Management|2022Cited by 19
Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT): A Preventable Cerebellar DisorderSarah Marmol, Jason Margolesky, Nestor Beltre|The Cerebellum|2024Cited by 8
Features in essential tremor and the development of Parkinson’s disease vs. parkinsonismHsien Lee Lau, Jason Margolesky, Sarah Marmol|Neurological Sciences|2020Cited by 5
Blepharoclonus in ParkinsonismJason Margolesky, Michael Benatar, Danielle S. Shpiner et al.|Neurology Clinical Practice|2023Cited by 4